{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:35:46Z","timestamp":1790760946820,"version":"4.1.0"},"reference-count":72,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["15\u201029667A"],"award-info":[{"award-number":["15\u201029667A"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["02.1.01\/0.0\/0.0\/16_019\/0000868"],"award-info":[{"award-number":["02.1.01\/0.0\/0.0\/16_019\/0000868"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Immunoglobulin light\u2010chain amyloidosis (AL amyloidosis) is a rare disease in which a small plasma cell clone produces toxic misfolded proteins that deposit in organs and impair their function. Currently, the only available treatment approach is the elimination of clonal plasma cells. However, a rapid strike that halts and possibly reverses organ damage is crucial. The development of agents that facilitate the clearance of pathological fibrillar deposits, therefore reducing the frailty of patients, is the needed supplement to plasma cell\u2010directed therapy. Monoclonal antibodies provide therapy against malignant plasma cells (daratumumab, isatuximab, elotuzumab) but they are also able to target and eliminate the amyloid from organs (NEOD001, CAEL\u2010101, dezamizumab). From the plasma cell\u2010directed group, daratumumab in monotherapy has proved to be extremely efficient in relapsed AL amyloidosis, exceeding its results in multiple myeloma. Compared to other agents, monoclonal antibodies possess the advantage of high selectivity and low toxicity and could potentially become future game\u2010changers in this field. Co\u2010targetting of the plasma cell clone and amyloid deposits shall together be translated in the revolutionary improved outcome of potentially curable AL amyloidosis.<\/jats:p>","DOI":"10.1111\/bjh.16436","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T04:29:46Z","timestamp":1582086586000},"page":"228-238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Monoclonal antibodies in the treatment of AL amyloidosis: co\u2010targetting the plasma cell clone and amyloid deposits"],"prefix":"10.1111","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-4218","authenticated-orcid":false,"given":"Tereza","family":"Popkova","sequence":"first","affiliation":[{"name":"Department of Haematooncology University Hospital Ostrava and Faculty of Medicine Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Ostrava and Faculty of Medicine Ostrava Czech Republic"},{"name":"Faculty of Medicine University of Ostrava Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-9253","authenticated-orcid":false,"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Ostrava and Faculty of Medicine Ostrava Czech Republic"},{"name":"Faculty of Medicine University of Ostrava Ostrava Czech Republic"},{"name":"Faculty of Science University of Ostrava Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0262-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118464"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2013.854766"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4947"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09494"},{"key":"e_1_2_9_7_1","unstructured":"Braet H. Zwaenepoel O.&Gettemans J.(2018)Serum amyloid P component nanobodies a new tool in amyloid research. InKumamoto Japan."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000126569.75419.74"},{"key":"e_1_2_9_9_1","unstructured":"Comenzo R. Kastritis E. Maurer M. Zonder J. Minnema M.C. Wechalekar A. Palladini G. Qin X. Vasey S. Aschan J. Vermeulen J.&Merlini G.(2019)Subcutaneous daratumumab + cyclophosphamide bortezomib and dexamethasone (CYBORD) in patients with newly diagnosed amyloid light chain (AL) amyloidosis: updated safety run\u2010in results of andromeda.Amsterdam Available at:https:\/\/library.ehaweb.org\/eha\/2019\/24th\/267458\/raymond.l.comenzo.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.and.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1550[Accessed July 8 2019]."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01936"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4015"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.06.009"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"e_1_2_9_16_1","first-page":"5577","article-title":"Incidence and prevalence of light chain amyloidosis: a population\u2010based study","volume":"130","author":"Duhamel S.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.643.643"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1584892"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118177"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0209-7"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.644.644"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1615428"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08036.x"},{"key":"e_1_2_9_25_1","unstructured":"Godara A. Siddiqui N. Lee L. Toskic D. Fogaren T. Varga C.&Comenzo R.(2019)Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement.Chicago Available at:http:\/\/abstracts.asco.org\/239\/AbstView_239_263947.html[Accessed July 8 2019]."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64639-1"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.021"},{"key":"e_1_2_9_28_1","unstructured":"Jaccard A. Arnulf B. Stoppa A.\u2010M. Karlin L. Perrot A. Macro M. Huart A. Frenzel L. Morel P. Dorvaux V. Merlini G. Palladini G. Lavergne D. Bridoux F.&Rousselle M.(2018)A prospective Phase II study of daratumumab in previously\u2010treated. In room A1. Available at:https:\/\/learningcenter.ehaweb.org\/eha\/2018\/stockholm\/214545\/arnaud.jaccard.a.prospective.phase.ii.study.of.daratumumab.in.html?f=topic=1574*media=3[Accessed February 14 2019]."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.004"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.01.004"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.90"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2351"},{"key":"e_1_2_9_33_1","first-page":"939","article-title":"CD38 c\u00edlen\u00e1 l\u00e9\u010dba u mnoho\u010detn\u00e9ho myelomu","volume":"64","author":"Jel\u00ednek T.","year":"2018","journal-title":"Vnit\u0159n\u00ed l\u00e9ka\u0159stv\u00ed"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.646.646"},{"key":"e_1_2_9_35_1","article-title":"Consolidation with a short course of daratumumab can significantly improve complete response rates in patients with AL amyloidosis or LCDD","author":"Kastritis E.","year":"2019","journal-title":"Amsterdam"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-763599"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15455"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.647.647"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5690.5690"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-453001"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.11.017"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751628"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1398235"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi0616605"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-629790"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-620302"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756528"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14897"},{"key":"e_1_2_9_53_1","unstructured":"Prothena Discontinues Development of NEOD001 for AL Amyloidosis(2019).Prothena Corporation plc. Available at:http:\/\/ir.prothena.com\/news-releases\/news-release-details\/prothena-discontinues-development-neod001-al-amyloidosis[Accessed June 9 2019]."},{"key":"e_1_2_9_54_1","unstructured":"Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis(2019)Prothena Corporation plc. Available at:http:\/\/ir.prothena.com\/news-releases\/news-release-details\/prothena-reports-results-phase-3-vital-amyloidosis-study-neod001[Accessed June 9 2019]."},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1205974"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504942"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3128"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705106"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662726"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771220"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112991"},{"key":"e_1_2_9_62_1","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott A.M.","year":"2012","journal-title":"Cancer Immunity"},{"key":"e_1_2_9_63_1","unstructured":"Search | GSK(2019) Available at:https:\/\/www.gsk.com\/en-gb\/search\/[Accessed October 11 2019]."},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01676"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722496"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0020-5"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.10.4299"},{"key":"e_1_2_9_68_1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2018-99-109769","article-title":"Treatment with AMG 420, an anti\u2010B\u2010cell maturation antigen (BCMA) bispecific T\u2010cell engager (BiTE\u00ae) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and\/or refractory (R\/R) multiple myeloma (MM) patients: results of a first\u2010in\u2010human (FIH) Phase I dose escalation study","volume":"132","author":"Topp M.S.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273797"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052686"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1805515115"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116801"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112902"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16436","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T18:53:48Z","timestamp":1694026428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/bjh.16436"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16436","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"2020-02-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}